ACC/AHA/NHLBI clinical advisory on the use and safety of statins

Journal of the American College of Cardiology

Volumn 40, Issue 3, 2002, Pages 567-572

  Pasternak, Richard C ^a   Smith Jr , Sidney C ^a   Bairey Merz, C Noel ^a   Grundy, Scott M ^a   Cleeman, James I ^a   Lenfant, Claude ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CREATINE KINASE; CYCLOSPORIN; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; MEVINOLIN; NEFAZODONE; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; STATIN; VERAPAMIL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY NECROSIS; MYOGLOBINURIA; MYOPATHY; MYOSITIS; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; CREATINE KINASE; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUSCULAR DISEASES; PYRIDINES; RISK FACTORS;

EID: 0037036822     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02030-2     Document Type: Review

References (36)

1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
3. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
8. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study
9. Cerivastatin and reports of fatal rhabdomyolysis
10. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
11. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
12. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
13. HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia
14. Drug treatment of dyslipoproteinemia
15. Nonalcoholic fatty liver disease
16. Statins and risk of polyneuropathy: A case-control study
17. Learning from the cerivastatin experience
18. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
19. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis
20. Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: Lipid-lowering and immunosuppressive effects
21. Drug interactions with HMG CoA reductase inhibitors
22. Does differing metabolism by cytochrome p450 have clinical importance?
23. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
24. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
25. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
26. Safety of combined pravastatin-gemfibrozil therapy
27. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
28. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia
29. Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: Additive effects of combination treatment on lipid regulation
30. Long-term treatment with pravastatin alone and in combination with gemfibrozil in familial type IIB hyperlipoproteinemia or combined hyperlipidemia
31. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia
32. HMG CoA reductase inhibitor-induced myotoxicity: Pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture
33. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
34. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
35. Lovastatin increases exercise-induced skeletal muscle injury